MAP
TBPH icon

Madison Avenue Partners’s Theravance Biopharma TBPH Stock Holding History

Madison Avenue Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157M Sell
9,212,252
-298,898
-3% -$4.95M 6.74% 6
2026
Q1 		$154M Hold
9,511,150
– – 6.71% 6
2025
Q4 		$178M Hold
9,511,150
– – 7.65% 6
2025
Q3 		$139M Hold
9,511,150
– – 8.29% 7
2025
Q2 		$105M Hold
9,511,150
– – 7% 6
2025
Q1 		$84.9M Hold
9,511,150
– – 7.21% 5
2024
Q4 		$89.5M Hold
9,511,150
– – 9.48% 4
2024
Q3 		$76.7M Buy
9,511,150
+999,800
+12% +$8.66M 7.11% 6
2024
Q2 		$72.2M Buy
8,511,350
+1,499,124
+21% +$13.5M 9.12% 4
2024
Q1 		$62.9M Hold
7,012,226
– – 10.15% 3
2023
Q4 		$78.8M Hold
7,012,226
– – 11.13% 3
2023
Q3 		$60.5M Hold
7,012,226
– – 8.59% 4
2023
Q2 		$72.6M Hold
7,012,226
– – 15.83% 3
2023
Q1 		$76.1M Hold
7,012,226
– – 16.36% 2
2022
Q4 		$78.7M Hold
7,012,226
– – 13.94% 2
2022
Q3 		$71.1M Sell
7,012,226
-257,358
-4% -$2.41M 15.25% 2
2022
Q2 		$65.9M Hold
7,269,584
– – 13.47% 2
2022
Q1 		$69.5M Buy
7,269,584
+621,559
+9% +$6.09M 12.98% 2
2021
Q4 		$73.5M Buy
6,648,025
+1,718,602
+35% +$15M 15.9% 2
2021
Q3 		$36.5M Buy
+4,929,423
New +$55.1M 8.08% 7

Other funds holding TBPH

WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Madison Avenue Partners's TBPH Position: Q2 2026 in Review

Madison Avenue Partners reduced its Theravance Biopharma (TBPH) stake by 3.1% in Q2 2026, selling an estimated $4.95M and leaving 9,212,252 shares worth $157M. The position accounts for 6.74% of the portfolio, ranked #6.

Madison Avenue Partners first reported a position in TBPH in Q3 2021 and has held it in 20 quarters since. The position peaked at $178M in Q4 2025. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Madison Avenue Partners held 9,212,252 shares of Theravance Biopharma worth $157M as of Q2 2026.
  • Madison Avenue Partners sold 298,898 Theravance Biopharma shares in Q2 2026, an estimated $4.95M.
  • Theravance Biopharma made up 6.74% of Madison Avenue Partners's portfolio in Q2 2026, its #6 holding.
  • Madison Avenue Partners first reported a position in Theravance Biopharma in Q3 2021 and has held it in 20 quarters since.
  • Madison Avenue Partners's Theravance Biopharma position peaked at $178M in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Madison Avenue Partners's 13F filing for Q2 2026, filed 14 Aug 2026.